3 Gene Therapy Stocks That Could Make You Rich
The FDA just approved another gene-altering cancer treatment that will save thousands of lives. Yescarta from Gilead Sciences (NASDAQ: GILD) teaches cancer patients' immune cells to seek out and destroy cancer cells with so much fervor that oncologists can hardly contain their excitement.
A pipeline full of similar therapies, and the means to develop them, earns Gilead a spot on this list, but you should know that today's best gene therapy stocks aren't limited to the field of cancer. While bluebird bio, Inc. (NASDAQ: BLUE) has cancer therapies in development, its experimental treatment for a rare chromosomal disease is barreling toward an approval. Finally, AveXis, Inc. (NASDAQ: AVXS) has taken aim at a muscle-wasting disorder with impressive results.
Careful monitoring of the gene therapy space turned up a few stocks that could make you rich. Image source: Getty Images.
Source: Fool.com
